Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
John Crawford
Job title: Managing Director
ACC 26: STEMI-DTU Trial – Primary Unloading and Delayed Reperfusion
Author(s): Navin K Kapur Added: 2 weeks ago
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.This prospective,… View more

Intervention

Heart Failure
Carlo De Asmundis
Carlo de Asmundis is a Professor in Cardiology at Vrije Universiteit Brussel, and Chair of the Heart Rhythm Management Center at Universitair Ziekenhuis Brussel, Begium. He also serves as Director of the Postgraduate Program in Cardiac Electrophysiology and Pacing at Vrije Universiteit Brussel.Prof de Asmundis graduated medical school in University Vita-Salute San Raffaele Hospital, Milan, Italy,… View more
AHA 24: The ENDEAVOR Trial
Author(s): Added: 1 year ago
AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).Dr Sanjiv Shah (Bluhm Cardiovascular Institute, Chicago, US) joins us onsite at AHA Conference to discuss the… View more

Heart Failure
AHA 24: The EMPEROR-Preserved Trial
Author(s): Andrew JS Coats Added: 1 year ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR… View more

Heart Failure
AHA 24: The VALOR-HCM Trial
Author(s): Milind Y Desai Added: 1 year ago
AHA Conference 2024 - 128-week results of VALOR-HCM investigating mavacamten treatment for patients with hypertrophic cardiomyopathy (HCM) referred for septal reduction therapy (SRT) procedures.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from VALOR-HCM (NCT04349072).VALOR-HCM is a randomized, double-blind, placebo-controlled, phase 3… View more

Heart Failure
Jonathan McKenna is Managing Director at Radcliffe Cardiology and can be contacted here. View more
Research Area(s) / Expertise:
ESC HF 25: The VELOCITY Study
Author(s): Stephen J Greene Added: 11 months ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an… View more

Heart Failure